Sort
34,240 grants matching “atherosclerosis”
Training Program in Molecular and Cellular Cardiology
$462,167Bruce D Gelb · Icahn School Of Medicine At Mount Sinai · T32 · FY2008 · HL
Vascular Function, Cognition, and Brain MRI in Atherosclerotic Vascular Disease
$462,162David J Moser · University Of Iowa · R01 · FY2012 · AG
Nlrp3 inflammasome activation in early diabetic retinopathy
$462,151Jayakrishna Ambati · University Of Virginia · R01 · FY2021 · EY
Mechanisms of action of drugs that prevent experimental diabetic retinopathy
$462,132Mara Lorenzi · Schepens Eye Research Institute · R01 · FY2011 · EY
In Vitro Human Tissue-Engineered Blood Vessel Disease Model of Progeria
$462,123George A Truskey · Duke University · R01 · FY2020 · HL
In Vitro Human Tissue-Engineered Blood Vessel Disease Model of Progeria
$462,123George A Truskey · Duke University · R01 · FY2019 · HL
PPARgamma, Endothelial Inflammation, and Atherosclerosis
$462,113University Of Rochester · P01 · FY2005 · HL
Role of Tissue Factor in Atherosclerosis
$462,054Nigel Mackman · Scripps Research Institute, The · P01 · FY2007 · HL
Multifactor Risk Reduction for Optimal Management in Peripheral Arterial Disease
$462,013Roberta K Oka · University Of California, San Francisco · R01 · FY2010 · NR
Hepatocyte Nuclear Factor 4alpha and Lipid Homeostasis
$462,000Yanqiao Zhang · Northeast Ohio Medical University · R15 · FY2010 · DK
The biological effect and the mode of action of the CXCL7-CXCL12 chemokine heterodimer
$462,000Yuri Nesmelov · University Of North Carolina Charlotte · R15 · FY2023 · CA
Role of Cu Transporter in EC Metabolism, ROS, and Atherosclerosis
$462,000Tohru Fukai · Augusta University · P01 · FY2025 · HL
Role of Cu Transporter in EC Metabolism, ROS, and Atherosclerosis
$462,000Tohru Fukai · Augusta University · P01 · FY2024 · HL
Post-DPP Follow-Up Study
$461,994Neil H. White · Washington University · U01 · FY2006 · DK
Fine-tuning CXCL12-mediated activities using Beta1-strand binding peptides
$461,992Didier Dreau · University Of North Carolina Charlotte · R15 · FY2023 · GM
The Cardiac Atlas Project: Establishment of a Cardiac MRI Database.
$461,826Alistair Andrew Young · University Of Auckland · R01 · FY2010 · HL
Cyclophilin A is a Novel Mediator of Pulmonary Arterial Hypertension
$461,786Bradford C Berk · University Of Rochester · R01 · FY2019 · HL
Cyclophilin A is a Novel Mediator of Pulmonary Arterial Hypertension
$461,786Bradford C Berk · University Of Rochester · R01 · FY2017 · HL
Cyclophilin A is a Novel Mediator of Pulmonary Arterial Hypertension
$461,786Bradford C Berk · University Of Rochester · R01 · FY2018 · HL
Interleukin 12 disruption provides beta cell and microvessel protection in type 2diabetes
$461,660Khalid Matrougui · Eastern Virginia Medical School · R01 · FY2020 · HL
Novel Bioresorbable Vascular Scaffolds with Uniform Biodegradation
$461,657Jaroslaw W Drelich · Michigan Technological University · R56 · FY2023 · HL
Project 1: HDL Function and Oxidation in Diabetic Atherosclerosis
$461,481Jay W Heinecke · University Of Washington · P01 · FY2016 · HL
Project 1: HDL Function and Oxidation in Diabetic Atherosclerosis
$461,481Jay W Heinecke · University Of Washington · P01 · FY2015 · HL
Macrophage Akt and IKKalpha signaling in apoptosis and atherosclerosis
$461,375Macrae F Linton · Vanderbilt University · R01 · FY2012 · HL
Subclinical CVD in African American Type 2 Diabetics
$461,357Barry Ira Freedman · Wake Forest University Health Sciences · R01 · FY2012 · DK